A947

A947 is a potent and selective SMARCA2 proteolysis-targeting chimera molecule (PROTAC) . A947 also is a potent and moderately selective SMARCA2 degrader. A947 has binding affinity to the SMARCA2 bromodomain with a Kd value of 93 nM. A947 can be used for the research of cancer[1].

Product Specifications

CAS Number

[2378056-80-3]

UNSPSC

12352005

Target

Apoptosis; Epigenetic Reader Domain; PROTACs

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; PROTAC

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/a947.html

Solubility

10 mM in DMSO

Smiles

NC1=C(C=C(C(C=CC=C2)=C2O)N=N1)N3C[C@H](CC4)N(C5=CC=NC(O[C@H](C6)C[C@@H]6OC(CC7)CCN7CC8CCN(C9=NOC([C@@H](C(C)C)C(N(C[C@@H]%10O)[C@@H](C%10)C(N[C@H](C%11=CC=C(C(SC=N%12)=C%12C)C=C%11)C)=O)=O)=C9)CC8)=C5)[C@H]4C3

Molecular Formula

C61H76N12O7S

Molecular Weight

1121.40

References & Citations

[1] Jennifer Cantley, et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat Commun. 2022 Nov 10;13 (1) :6814.